Compare JetBlue Airways Corporation (JBLU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Merck & Co., Inc. — how do they compare? JetBlue Airways Corporation trades at $3.84 (market cap $1.48B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 237.4× JetBlue Airways Corporation's market cap, and Merck & Co., Inc. pays a 2.39% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Merck & Co., Inc. for 98 Days on average.
| JBLU | MRK | |
|---|---|---|
Market Cap | $1.48B | $351.28B |
Volume | 30,275,693 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $6.46 | $156.43 |
52-Week Low | $3.84 | $82.49 |
Typical Hold Time | 44 Days | 98 Days |
Enterprise Value | $8.84B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.92, down 1.26% today, reflecting ongoing operational challenges. The airline faces persistent profitability issues with a net income margin of -9.32% and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations but followed two consecutive misses. Technical indicators show bearish momentum with the stock trading near key support levels. The company continues expansion efforts with new Colombia routes while grappling with high fuel costs and capacity constraints.
Investment outlook remains cautious given sustained losses and high debt levels. The consensus price target of $5.89 offers 50% upside potential, but execution risks from fuel price volatility and competitive pressures persist. Analyst sentiment leans neutral with 62% hold ratings, suggesting limited near-term catalysts for significant price appreciation despite attractive valuation multiples.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
